CNTA Centessa Pharmaceuticals PLC ADR

$17.01

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About Centessa Pharmaceuticals PLC ADR

Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers drugs that change and improve the lives of patients. The company is headquartered in Cambridge, the United Kingdom.

Website: https://centessa.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1847903
Address
THE DOROTHY HODGKIN BUILDING, BABRAHAM RESEARCH CAMPUS, BABRAHAM, CAMBRIDGE, GB
Valuation
Market Cap
$1.64B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
4.08
Performance
EPS
$-2.06
Dividend Yield
—
Profit Margin
0.00%
ROE
-73.90%
Technicals
50D MA
$15.24
200D MA
$14.87
52W High
$19.09
52W Low
$7.75
Fundamentals
Shares Outstanding
133M
Target Price
$31.25
Beta
1.54

CNTA EPS Estimates vs Actual

● Estimated
● Actual

CNTA News & Sentiment

Aug 12, 2025 • GlobeNewswire NEUTRAL
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025
Advancing a broad, potential best-in-class orexin receptor 2 ( OX2R ) agonist franchise, with key data readouts expected this year ...
Aug 08, 2025 • GlobeNewswire NEUTRAL
Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025
Tokyo, Japan and Cambridge, UK, 8 August 2025 - Nxera Pharma ( "the Company" or "Nxera". TSE: 4565 ) provides an update on operational activities and reports its consolidated results for the second quarter and first half ended 30 June 2025. The full report can be found here.
Jul 04, 2025 • GlobeNewswire NEUTRAL
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 ( OX2R ) Agonist
Tokyo, Japan and Cambridge, UK, 4 July 2025 - Nxera Pharma Co., Ltd. ( "Nxera" or "the Company". TSE 4565 ) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals pursuant to its research collaboration with Centessa.
Jun 16, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Centessa Pharmaceuticals ( CNTA ) Upgraded to Buy: What Does It Mean for the Stock?
Centessa Pharmaceuticals (CNTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Jun 16, 2025 • GlobeNewswire NEUTRAL
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application ( IND ) for ORX142, a Novel Orexin Receptor 2 ( OX2R ) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
BOSTON and LONDON, June 16, 2025 ( GLOBE NEWSWIRE ) -- Centessa Pharmaceuticals plc ( Nasdaq: CNTA ) , a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration ( FDA ) has cleared the IND to initiate a Phase 1 clinical study of ORX142 in healthy ...
Jun 04, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Wall Street Analysts Think Centessa Pharmaceuticals ( CNTA ) Could Surge 138.77%: Read This Before Placing a Bet
The consensus price target hints at a 138.8% upside potential for Centessa Pharmaceuticals (CNTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Sentiment Snapshot

Average Sentiment Score:

0.161
50 articles with scored sentiment

Overall Sentiment:

Bullish

CNTA Reported Earnings

Mar 24, 2025
Dec 31, 2024 (Pre market)
-0.23 Surprise
  • Reported EPS: $-0.58
  • Estimate: $-0.35
  • Whisper: —
  • Surprise %: -64.8%
Nov 12, 2024
Sep 30, 2024 (Pre market)
0.02 Surprise
  • Reported EPS: $-0.37
  • Estimate: $-0.39
  • Whisper: —
  • Surprise %: 4.5%
Aug 13, 2024
Jun 30, 2024 (Pre market)
-0.0 Surprise
  • Reported EPS: $-0.40
  • Estimate: $-0.40
  • Whisper: —
  • Surprise %: -0.8%
May 13, 2024
Mar 31, 2024 (Post market)
0.04 Surprise
  • Reported EPS: $-0.38
  • Estimate: $-0.42
  • Whisper: —
  • Surprise %: 9.5%
Mar 28, 2024
Dec 31, 2023 (Post market)
0.1 Surprise
  • Reported EPS: $-0.38
  • Estimate: $-0.48
  • Whisper: —
  • Surprise %: 20.8%
Nov 13, 2023
Sep 30, 2023 (Post market)
0.12 Surprise
  • Reported EPS: $-0.40
  • Estimate: $-0.52
  • Whisper: —
  • Surprise %: 23.1%
Aug 14, 2023
Jun 30, 2023 (Pre market)
0.23 Surprise
  • Reported EPS: $-0.26
  • Estimate: $-0.49
  • Whisper: —
  • Surprise %: 46.9%
May 12, 2023
Mar 31, 2023 (Pre market)
-0.12 Surprise
  • Reported EPS: $-0.53
  • Estimate: $-0.41
  • Whisper: —
  • Surprise %: -29.3%
Mar 30, 2023
Dec 31, 2022 (Pre market)
0.03 Surprise
  • Reported EPS: $-0.45
  • Estimate: $-0.48
  • Whisper: —
  • Surprise %: 6.2%

Financials